About the Ypsomed Group
The Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 30 years’ experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of injections pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands, mylife™ Diabetescare directly to patients or through pharmacies and clinics, and under YDS Ypsomed Delivery Systems as business-to-business to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs around 1 500 employees.
Ypsomed Diabetes Care
With mylife™ Diabetescare Ypsomed is successful in direct business with products and services for people with diabetes mellitus. Ypsomed is expanding into new markets worldwide with a networked portfolio. The objective is to further network the products and thus offer users real added value.
Ypsomed Delivery Systems
Ypsomed offers pharmaceutical and biotech customers injection systems and related services under the YDS brand, Ypsomed Delivery Systems. The platform approach allows Ypsomed to meet customer requirements without risks and in flexible production quantities. In future, the platform products will be supplemented by digital products.
In the 2018/19 financial year, our sales will be in the same order of magnitude as in financial year 2017/18. At the EBIT level, we expect an amount of between CHF 61 million and CHF 76 million for the 2018/19 financial year.
Key financial figures: multi-year overview
|In thousand CHF||2017/18||2016/17||2015/16||2014/15|
|Sales of goods and services||466119||389 555||336 922||306 632|
|Gross Profit||139825||125 478||103 187||85 850|
|Operating Profit||61070||55 298||44 435||28 546|
|Net Profit||52060||46 247||35 812||19 395|
|EBITDA1||95539||87 763||73 270||57 369|
|Cash flow from operating activities||53269||75 064||76 687||41 381|
|Year-end headcount||1451||1 314||1 166||1 050|
1 Operating proﬁt before depreciation and Amortisation.